Clinical Case Reports (Oct 2022)

Successful rechallenge with cisplatin following cisplatin induced ischemic cerebrovascular accident in a patient with small cell lung cancer

  • Farah Rashid,
  • Nabil E. Omar,
  • Hassan Aaekl,
  • Ussama Al Homsi,
  • Alaaeldin Shablak

DOI
https://doi.org/10.1002/ccr3.6469
Journal volume & issue
Vol. 10, no. 10
pp. n/a – n/a

Abstract

Read online

Abstract Cisplatin is a widely used platinum‐based chemotherapy agent. Its common adverse effects are neuropathy, nephrotoxicity, electrolyte abnormality, and rarely causing thrombotic vascular toxicity. We present a patient known to have small‐cell lung cancer who developed ischemic cerebrovascular accident (CVA) after receiving chemotherapy regimen including cisplatin.

Keywords